rs11554290
|
|
C |
0.700 |
CausalMutation |
CLINVAR |
BRAF mutation predicts sensitivity to MEK inhibition.
|
16273091 |
2006 |
rs121913237
|
|
G |
0.700 |
CausalMutation |
CLINVAR |
BRAF mutation predicts sensitivity to MEK inhibition.
|
16273091 |
2006 |
rs121913237
|
|
A |
0.700 |
CausalMutation |
CLINVAR |
BRAF mutation predicts sensitivity to MEK inhibition.
|
16273091 |
2006 |
rs121913237
|
|
T |
0.700 |
CausalMutation |
CLINVAR |
BRAF mutation predicts sensitivity to MEK inhibition.
|
16273091 |
2006 |
rs121913250
|
|
T |
0.700 |
CausalMutation |
CLINVAR |
BRAF mutation predicts sensitivity to MEK inhibition.
|
16273091 |
2006 |
rs121913250
|
|
A |
0.700 |
CausalMutation |
CLINVAR |
BRAF mutation predicts sensitivity to MEK inhibition.
|
16273091 |
2006 |
rs11554290
|
|
C |
0.700 |
CausalMutation |
CLINVAR |
AZD6244 (ARRY-142886), a potent inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase 1/2 kinases: mechanism of action in vivo, pharmacokinetic/pharmacodynamic relationship, and potential for combination in preclinical models.
|
17699718 |
2007 |
rs121913237
|
|
A |
0.700 |
CausalMutation |
CLINVAR |
AZD6244 (ARRY-142886), a potent inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase 1/2 kinases: mechanism of action in vivo, pharmacokinetic/pharmacodynamic relationship, and potential for combination in preclinical models.
|
17699718 |
2007 |
rs121913237
|
|
T |
0.700 |
CausalMutation |
CLINVAR |
AZD6244 (ARRY-142886), a potent inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase 1/2 kinases: mechanism of action in vivo, pharmacokinetic/pharmacodynamic relationship, and potential for combination in preclinical models.
|
17699718 |
2007 |
rs121913237
|
|
G |
0.700 |
CausalMutation |
CLINVAR |
AZD6244 (ARRY-142886), a potent inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase 1/2 kinases: mechanism of action in vivo, pharmacokinetic/pharmacodynamic relationship, and potential for combination in preclinical models.
|
17699718 |
2007 |
rs121913250
|
|
T |
0.700 |
CausalMutation |
CLINVAR |
AZD6244 (ARRY-142886), a potent inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase 1/2 kinases: mechanism of action in vivo, pharmacokinetic/pharmacodynamic relationship, and potential for combination in preclinical models.
|
17699718 |
2007 |
rs121913250
|
|
A |
0.700 |
CausalMutation |
CLINVAR |
AZD6244 (ARRY-142886), a potent inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase 1/2 kinases: mechanism of action in vivo, pharmacokinetic/pharmacodynamic relationship, and potential for combination in preclinical models.
|
17699718 |
2007 |
rs11554290
|
|
C |
0.700 |
CausalMutation |
CLINVAR |
Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis.
|
20619739 |
2010 |
rs121913237
|
|
A |
0.700 |
CausalMutation |
CLINVAR |
Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis.
|
20619739 |
2010 |
rs121913237
|
|
G |
0.700 |
CausalMutation |
CLINVAR |
Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis.
|
20619739 |
2010 |
rs121913237
|
|
T |
0.700 |
CausalMutation |
CLINVAR |
Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis.
|
20619739 |
2010 |
rs121913250
|
|
T |
0.700 |
CausalMutation |
CLINVAR |
Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis.
|
20619739 |
2010 |
rs121913250
|
|
A |
0.700 |
CausalMutation |
CLINVAR |
Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis.
|
20619739 |
2010 |
rs11554290
|
|
C |
0.700 |
CausalMutation |
CLINVAR |
NRAS mutations are rare in colorectal cancer.
|
20736745 |
2010 |
rs121913237
|
|
A |
0.700 |
CausalMutation |
CLINVAR |
NRAS mutations are rare in colorectal cancer.
|
20736745 |
2010 |
rs121913237
|
|
T |
0.700 |
CausalMutation |
CLINVAR |
NRAS mutations are rare in colorectal cancer.
|
20736745 |
2010 |
rs121913237
|
|
G |
0.700 |
CausalMutation |
CLINVAR |
NRAS mutations are rare in colorectal cancer.
|
20736745 |
2010 |
rs121913250
|
|
T |
0.700 |
CausalMutation |
CLINVAR |
NRAS mutations are rare in colorectal cancer.
|
20736745 |
2010 |
rs121913250
|
|
A |
0.700 |
CausalMutation |
CLINVAR |
NRAS mutations are rare in colorectal cancer.
|
20736745 |
2010 |
rs11554290
|
|
C |
0.700 |
CausalMutation |
CLINVAR |
Frequency of KRAS, BRAF, and NRAS mutations in colorectal cancer.
|
21305640 |
2011 |